U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Spoonamore Drug Co Inc - 455964 - 05/17/2018
  1. Warning Letters

CLOSEOUT LETTER

Spoonamore Drug Co Inc MARCS-CMS 455964 —

Recipient:
Spoonamore Drug Co Inc

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
Division of Pharmaceutical Quality Operations III
300 River Place, Suite 5900
Detroit, MI 48207
Telephone: (313) 393-8100
Fax: (313) 393-8139 

May 17, 2018

UPS NEXT DAY
SIGNATURE REQUIRED

Steven D. Williams
President and Owner
Spoonamore Drug Company, Inc. dba
Louisville Pharmacy and Custom Script
4014 Dutchmans Lane, Suite 11
Louisville, KY 40207

Dear Mr. Williams:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [CIN-16-455964-04] issued on December 18, 2015. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Nicholas F. Lyons
Compliance Director
Division of Pharmaceutical Quality Operations III 

Back to Top